Tumor-derived extracellular vesicles inhibit osteogenesis and exacerbate myeloma bone disease
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: As a hallmark driver of multiple myeloma (MM), MM bone disease (MBD) is unique in that it is characterized by severely impaired osteoblast activity resulting from blocked osteogenesis in bone marrow-derived mesenchymal stem cells (BM-MSCs).The mechanisms underlying this preferential blockade are incompletely understood.Methods: miRNA expression of MM cell-derived extracellular vesicles (MM-EVs) was detected by RNA sequencing.MM-EVs impaired osteogenesis and exacerbated MBD were in vitro and in vivo validated by histochemical staining, qPCR and micro-CT.We additionally examined the correlation between CD138 + circulating EVs (cirEVs) count and bone lesion in de novo MM patients.Results: Here, by sequencing and bioinformatics analysis, we found that MM-EVs were enriched in various molecules negatively regulating osteogenesis.We experimentally verified that MM-EVs inhibited BM-MSC osteogenesis, induced elevated expression of miR-103a-3p inhibiting osteogenesis in BM-MSCs, and increased cell viability and interleukin-6 secretion in MM cells.In a mouse model, MM-EVs that were injected into the marrow space of the left tibia led to impaired osteogenesis and exacerbated MBD and MM progression.Furthermore, the levels of CD138 + cirEVs in the peripheral blood were positively correlated with the number of MM bone lesions in MM patients.Conclusions: These findings suggest that MM-EVs play a pivotal role in the development of severely impaired osteoblast activity, which represents a novel biomarker for the precise diagnosis of MBD and a compelling rationale for exploring MM-EVs as a therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Communication by Extracellular Vesicles: Where We Are and Where We Need to Go
Tkach, M., & Théry, C. (2016) · Cell · doi:10.1016/j.cell.2016.01.043 · Cited by 3,444 · cited 1×
“Recently, a growing body of evidence has shown that extracellular vesicles (EVs) are a previously unappreciated mechanism for intercellular communication, and cancer cells can release EVs that contain a variety of molecules, such as proteins, RNAs and microRNAs (miRNAs), to influence the microenvironment [14-20].”
BackgroundMicroenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth
Zhang, L., Zhang, S., Yao, J., Lowery, F. J., Zhang, Q., Huang, W.-C., Li, P., Li, M., Wang, X., Zhang, C., et al. (2015) · Nature · doi:10.1038/nature15376 · Cited by 1,175 · cited 1×
“The key roles of these miRNAs enriched in EVs that are specifically released by parental cells and transferred to target cells have also been demonstrated by many studies [43-47].”
BackgroundSelf-citationBiological and therapeutic impact of intratumor heterogeneity in cancer evolution
McGranahan, N., & Swanton, C. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.001 · Cited by 1,077 · cited 2×
“MM cells develop via forward-feedback mechanisms with local BM-MSCs, and the cycle of interactions between MM cells and BM-MSCs contributes to the incurability of MBD and myeloma [1, 10, 12, 13].”
BackgroundClinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921 · cited 1×
“Currently, there is an ongoing dilemma in the management of patients with smoldering MM (SMM), which is an intermediate clinically-defined stage associated with a much higher risk of progression to malignancy (~10% per year) than monoclonal gammopathy of undetermined significance (MGUS; ~1% per year) [54, 55].”
BackgroundOsteoblast and osteocyte: Games without frontiers
Capulli, M., Paone, R., & Rucci, N. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.05.003 · Cited by 413 · cited 11×
“To observe the uptake of MM-EVs into the BM-MSCs or MM cells, the MM-EVs were stained with PKH26 (1 μM), and the cells were then incubated with the PKH26-stained MM-EVs for 2, 4, 6, 12 or 24 h at 37 °C.”
BackgroundInfluentialThe osteoblastic niche in the context of multiple myeloma
Toscani, D., Bolzoni, M., Accardi, F., Aversa, F., & Giuliani, N. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12578 · Cited by 52 · cited 2×
“bortezomib, the mainstay treatments for MBD, bone fractures and osteoporosis continue to persist, and the devastating skeletal complications associated with this disease are a significant cause of morbidity and mortality in MM patients [4-7].”
Background
Cited by
Lei, Q., Gao, F., Liu, T., Ren, W., Chen, L., Cao, Y., Chen, W., Guo, S., Zhang, Q., Chen, W., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz8697 · Cited by 170
“EV isolation EVs (diameter > 100 nm) were purified by differential centrifugation processes, as we previously described (65, 66).”
MethodSelf-citationGarcía-Sánchez, D., González-González, A., Alfonso-Fernández, A., Del Dujo-Gutiérrez, M., & Pérez-Campo, F. M. (2023) · World Journal of Stem Cells · doi:10.4252/wjsc.v15.i5.421 · Cited by 32
Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology
Raimondi, L., De Luca, A., Giavaresi, G., Raimondo, S., Gallo, A., Taiana, E., Alessandro, R., Rossi, M., Neri, A., Viglietto, G., et al. (2020) · Non-Coding RNA · doi:10.3390/ncrna6030037 · Cited by 16
Wu, Y., Yao, X., Shi, X., Xu, Z., Ren, J., Shi, M., Li, M., Liu, J., & Du, X. (2024) · Apoptosis · doi:10.1007/s10495-023-01920-7 · Cited by 10
Metadata
- Authors
- Zhang, L., Lei, Q., Wang, H., Xu, C., Liu, T., Kong, F., Yang, C., Yan, G., Sun, L., Zhao, A., Chen, W., Hu, Y., Xie, H., Cao, Y., Fu, F., Yuan, G., Chen, Z., Guo, A.-Y., & Li, Q.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2019
- Volume
- 9
- Issue
- 1
- Pages
- 196-209
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2904267251
- Cited by
- 71
- References
- 6
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.